Neogen Corporation’s third-quarter fiscal 2024 earnings per share stood at 12 cents, on par with the previous year but missed the Zacks Consensus Estimate by 14.3%. Revenues displayed a 4.8% increase year over year, totaling $228.8 million. However, the Zacks Consensus Estimate was slightly missed by 0.5%.
Diving into Segmental Revenue Performance
In the third quarter, Food Safety revenues rose to $157.8 million, driven by a 4.1% improvement from the prior year. Neogen’s Animal Safety segment saw revenues of $71.1 million, marking a 6.5% year-over-year increase. However, the Genomics business experienced a core revenue decline in the mid-single-digit range globally.
Margin Expansion and Financial Standing
Neogen boasted an 8.3% year-over-year increase in gross profit to $116.9 million, with a gross margin expansion of 162 basis points to 51.1%. The company ended the quarter with cash and cash equivalents of $161.4 million and held non-current liabilities indicating outstanding debt along with borrowing availability.
Insight into Full-Year Outlook
For fiscal 2024, Neogen expects revenues between $910 million and $920 million, demonstrating a slight revision from the initial guidance. The company identifies capital expenditures, particularly related to the integration of the former 3M Food Safety Division, as a substantial financial consideration.
Analysis and Future Prospects
Despite challenges in operational efficiency and order fulfillment rates impacting revenue forecasts, Neogen showcased a year-over-year revenue increase. The strategic integration of the former 3M Food Safety business positions the company for future growth, offering a glimpse of optimism amidst operational hurdles.
Market Position and Comparisons
Neogen currently maintains a Zacks Rank #4 (Sell) status. In comparison, other notable players in the medical sector like Insulet, Exact Sciences, and Cardinal Health exhibit varying growth patterns and financial performance, providing a comprehensive overview of the industry landscape and investment considerations.
Exploring the Bitcoin Profit Phenomenon
Discover the Bitcoin Profit Phenomenon
Zacks Investment Research brings you a unique opportunity to delve into the realm of massive profits with the world’s first and largest decentralized form of currency.
Reflections on the past reveal staggering returns for Bitcoin during recent presidential election years: a formidable +272.4% in 2012, a noteworthy +161.1% in 2016, and an astonishing +302.8% in 2020.
What does the future hold? Zacks predicts a significant surge ahead. Get insights with “Bitcoin: A Tumultuous Yet Resilient History” by clicking the link below.
Download Our Free Report Today >>
Are you seeking the latest recommendations from Zacks Investment Research? Download “7 Best Stocks for the Next 30 Days” now by clicking the link below.
Click Here for Free Stock Analysis Report
Dive deeper into the stock market with insightful reports for the following companies:
Cardinal Health, Inc. (CAH) : Free Stock Analysis Report
Neogen Corporation (NEOG) : Free Stock Analysis Report
Insulet Corporation (PODD) : Free Stock Analysis Report
Exact Sciences Corporation (EXAS) : Free Stock Analysis Report
For further insights, visit Zacks.com for more information.
The thoughts put forth in this content are the musings of the author and do not necessarily mirror those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
